中文

Vera (VERA)

Biotech

Close on Nov 11, 2026 (from our latest Long View update): $30.48

Market value
$2.2Bat the Nov 11 close
Cash used, 12 months
$377M12 months to Sep 30, 2026 (10-Q)
Net cash
$309Mat Sep 30, 2026
Worst fall since listing
−84.9%Nov 30, 2021 to Jan 9, 2023; back to that high in Jan 2024

About the company

Latest

  • Down 1.2% Quarterly
    Vera Q3 2026: first Trutakna sales of $10.3M, about half inventory; a rival's FDA date nears

The Long View

Vera listed in 2021 with atacicept, a drug it licensed from Merck KGaA’s affiliate Ares, and funded two positive mid- and late-stage trials in IgAN through five share sales and a loan.

▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash

Updated Nov 11, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for Vera, FY2020–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Free cash flow was positive in 0 of the 6 years shown; FY2025: −$242M. Each year's figures are in the table below. −$300M−$200M−$100M$0 ’20 ’21 ’22 ’23 ’24 ’25

Free cash flow was positive in 0 of the 6 years shown; FY2025: −$242M.

Margins

Margins are not charted: fewer than two years with revenue and operating income.

Diluted share count

The diluted share count rose 378% from FY2021 to FY2025, to 64M. Each year's figures are in the table below. 0M20M40M60M80M ’21’22’23’24’25

The diluted share count rose 378% from FY2021 to FY2025, to 64M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025———−$300M−$241M$0.6M−$242M
FY2024———−$152M−$135M$1.0M−$136M
FY2023———−$96M−$92M$0.1M−$92M
FY2022———−$89M−$68M$0.1M−$68M
FY2021———−$33M−$24M$5M−$29M
FY2020———−$53M−$35M$0.1M−$35M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202564M$715M$75M$38M—$0
FY202455M$641M$51M$21M—$0.0M
FY202343M$161M$50M$11M—$0
FY202227M$115M$25M$9M——
FY202113M$80M$5M$3M——
FY2020—$54M$0$0.3M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 5, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearVERAS&P 500
2019—+31.5%
2020—+18.4%
2021+132.3%†+28.7%
2022−27.6%−18.1%
2023−20.5%+26.3%
2024+175.0%+25.0%
2025+19.7%+17.9%
2026 to date−47.2%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (May 14, 2021); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Vera

What does Vera Therapeutics sell?
One approved product, Trutakna (atacicept), a once-weekly self-injection for IgA nephropathy (IgAN), an immune disease that damages the kidneys. It blocks BAFF and APRIL, two signalling proteins that drive the antibody-producing B cells behind the disease. Vera began selling it in July 2026. More in the Long View →
Why is Trutakna's approval called accelerated?
The FDA approved it on Jul 7, 2026 to reduce proteinuria (protein in the urine), an early marker, in adults with primary IgAN at risk of disease progression. Continued approval is subject to confirmatory data. More in the Long View →
How protected is Trutakna from competition?
Trutakna has 12 years of US biologic exclusivity from approval, to Jul 7, 2038 (our calculation). That bars biosimilar copies relying on Trutakna's data, not independently developed drugs. Vertex's competing drug povetacicept also blocks BAFF and APRIL. More in the Long View →
What does Vera owe on Trutakna?
Vera licensed atacicept from Ares Trading, an affiliate of Merck KGaA. It owes Ares milestones, including up to $515.0M of sales milestones, plus tiered royalties of "low double-digit to mid-teen" percentages on net sales. More in the Long View →
What financing constraints does Vera's Oxford loan impose?
The Oxford loan is secured by substantially all assets except intellectual property. Vera has agreed not to pledge that intellectual property to other lenders, subject to exceptions in the agreement, and the loan limits mergers and changes in control. More in the Long View →
What's coming up for Vera's pipeline in the next 12 months?
Vera expects potential full approval of Trutakna in adults with primary IgAN in mid-2027, subject to FDA review of its sBLA submitted Nov 3, 2026. It also expects to submit its application to the EMA for standard marketing authorisation in Q1 2027. As of Nov 5, 2026 More in the Long View →

Disclosure: one or more of our editors own shares of Vera (VERA) as a long-term investment.